← Shanghai Allist Pharmaceuticals Co. Ltd. A overview

Shanghai Allist Pharmaceuticals Co. Ltd. A vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shanghai Allist Pharmaceuticals Co. Ltd. A (688578.CG)

Q3 202618 Aug – 7 Oct 2026

▲2▼2

Allist's core lung-cancer drug fails global trial, but buyback and dividends cushion

Core drug fails global Phase III trial Allist's main drug, furmonertinib, failed a global Phase III trial for a specific lung-cancer mutation. Since this drug is about 98.7% of Allist's revenue, the failure raises doubts about future growth and overseas milestone payments, pushing the stock down.
This is the biggest new negative event, directly threatening the company's main revenue source.
Buyback plan supports the stock Allist's chairman proposed buying back 100–200 million yuan of shares for employee incentives. Buybacks can lift the stock price by reducing shares outstanding and signaling management's confidence, offering a counterweight to the trial failure.
This is a new positive action that directly offsets the negative trial news.
Strong first-half profit and dividend Allist reported first-half net profit up 46.6% to 1.54 billion yuan and revenue up 39.9%. It also plans a cash dividend of 6 yuan per 10 shares (270 million yuan total). Strong earnings and cash returns support the stock.
These are new financial results and a dividend plan that show fundamental strength.
Procurement suspension report adds uncertainty A report said furmonertinib was suspended from procurement at a major hospital. Allist said it is verifying the claim. If true, it could hurt sales, but the company says operations are normal, so the impact is uncertain.
This is a new potential regulatory issue that could affect sales of the core drug.

September 202618 Aug – 7 Oct 2026

▲2▼2

Allist's core lung-cancer drug fails global trial, but buyback and dividends cushion

Core drug fails global Phase III trial Allist's main drug, furmonertinib, failed a global Phase III trial for a specific lung-cancer mutation. Since this drug is about 98.7% of Allist's revenue, the failure raises doubts about future growth and overseas milestone payments, pushing the stock down.
This is the biggest new negative event, directly threatening the company's main revenue source.
Buyback plan supports the stock Allist's chairman proposed buying back 100–200 million yuan of shares for employee incentives. Buybacks can lift the stock price by reducing shares outstanding and signaling management's confidence, offering a counterweight to the trial failure.
This is a new positive action that directly offsets the negative trial news.
Strong first-half profit and dividend Allist reported first-half net profit up 46.6% to 1.54 billion yuan and revenue up 39.9%. It also plans a cash dividend of 6 yuan per 10 shares (270 million yuan total). Strong earnings and cash returns support the stock.
These are new financial results and a dividend plan that show fundamental strength.
Procurement suspension report adds uncertainty A report said furmonertinib was suspended from procurement at a major hospital. Allist said it is verifying the claim. If true, it could hurt sales, but the company says operations are normal, so the impact is uncertain.
This is a new potential regulatory issue that could affect sales of the core drug.

Latest18 Aug – 7 Oct 2026

▲2▼2

Allist's core lung-cancer drug fails global trial, but buyback and dividends cushion

Core drug fails global Phase III trial Allist's main drug, furmonertinib, failed a global Phase III trial for a specific lung-cancer mutation. Since this drug is about 98.7% of Allist's revenue, the failure raises doubts about future growth and overseas milestone payments, pushing the stock down.
This is the biggest new negative event, directly threatening the company's main revenue source.
Buyback plan supports the stock Allist's chairman proposed buying back 100–200 million yuan of shares for employee incentives. Buybacks can lift the stock price by reducing shares outstanding and signaling management's confidence, offering a counterweight to the trial failure.
This is a new positive action that directly offsets the negative trial news.
Strong first-half profit and dividend Allist reported first-half net profit up 46.6% to 1.54 billion yuan and revenue up 39.9%. It also plans a cash dividend of 6 yuan per 10 shares (270 million yuan total). Strong earnings and cash returns support the stock.
These are new financial results and a dividend plan that show fundamental strength.
Procurement suspension report adds uncertainty A report said furmonertinib was suspended from procurement at a major hospital. Allist said it is verifying the claim. If true, it could hurt sales, but the company says operations are normal, so the impact is uncertain.
This is a new potential regulatory issue that could affect sales of the core drug.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.